Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Increased Risk of Hypertension Onset Among Patients With Narcolepsy Newly Treated With High-Sodium Oxybate
Sleep
P5 - Poster Session 5 (11:45 AM-12:45 PM)
11-002
High-sodium oxybate, a recommended narcolepsy treatment, contains a high-sodium content warning in its US Food and Drug Administration–approved labeling. The sodium-hypertension relationship is well established. 
This study compared intermediate-term risk (≤180 days) of new-onset hypertension among normotensive patients with narcolepsy initiating high-sodium oxybate (SXB cohort) with those not initiating high-sodium oxybate (controls). 
MarketScan® claims (1/2014 to 2/2020) were analyzed. Eligible adults had continuous enrollment and ≥1 narcolepsy claim or prescription for sodium oxybate. Patients with a history of hypertension, use of antihypertensives, and prior use of sodium oxybate were excluded. In a sensitivity analysis, patients with a history of cardiovascular disease (CVD) were also excluded. Two endpoints were assessed: 1) a composite of new-onset hypertension diagnosis or initiation of antihypertensive medication and 2) new-onset hypertension diagnosis alone. Propensity-score 1:2 matching was applied to balance baseline characteristics. Risk per 100 patients and adjusted odds ratios (ORs) were reported with 95% confidence intervals (CIs). 

A total of 954 and 1906 patients were included in the SXB and control cohorts, respectively. Risk of the composite endpoint per 100 patients was higher in SXB (6.60) than control (4.20) cohorts (OR=1.61; 95% CI, 1.15–2.27); risk of new-onset hypertension per 100 patients was higher in SXB (0.94) than control (0.52) cohorts (OR=1.81; 95% CI, 0.73–4.46). In the sensitivity analysis, risk of the composite endpoint per 100 patients was higher in SXB (6.22) than control (4.06) cohorts (OR=1.57; 95% CI, 1.10–2.24); risk of new-onset hypertension per 100 patients was higher in SXB (0.89) than control (0.44) cohorts (OR=2.01; 95% CI, 0.75–5.36).

This study showed increased risk of new-onset hypertension among normotensive patients with narcolepsy treated with sodium oxybate, even among patients without history of CVD. Clinicians should consider the cardiovascular risk associated with high-sodium oxybate. 
Authors/Disclosures
Wayne Macfadden, MD,PT
PRESENTER
Dr. Macfadden has received personal compensation for serving as an employee of Jazz pharma. Dr. Macfadden has stock in Jazz pharma.
Rami Ben-Joseph, PhD Dr. Ben-Joseph has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Ben-Joseph has stock in Jazz Pharmaceuticals.
Virend Somers Virend Somers has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz Pharmaceuticals . Virend Somers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Respicardia. Virend Somers has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer . Virend Somers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Baker Tilly. The institution of Virend Somers has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sleep Number . Virend Somers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institutes Health . The institution of Virend Somers has received research support from National Institutes Health. The institution of Virend Somers has received research support from Sleep Number .
Jed Black, MD (Jazz Pharmaceuticals) Jed Black, MD has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Jed Black, MD has stock in Jazz Pharmaceuticals. Jed Black, MD has stock in .
Ralph Dagostino, Jr., PhD (Wake Forest University School of Medicine) Dr. Dagostino has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz Pharmaceutical . Dr. Dagostino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Dagostino has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Exelixis. Dr. Dagostino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MEI Pharma. Dr. Dagostino has received research support from NIH.
Ragy Saad, Other (Jazz Pharmaceuticals) Mr. Saad has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Saad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidinno Outcomes Research Inc.. Mr. Saad has received stock or an ownership interest from Jazz Pharmaceuticals.
Mat D. Davis Mat D. Davis has received personal compensation for serving as an employee of Teva pharmaceuticals. Mat D. Davis has received stock or an ownership interest from Teva Pharmaceuticals.
Katherine Mues, PhD (Aetion) Dr. Mues has received personal compensation for serving as an employee of Aetion.
Clark Jackson Ms. Jackson has received personal compensation for serving as an employee of Aetion. Ms. Jackson has stock in Aetion.
Weiyi Ni, PhD Dr. Ni has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Ni has stock in Jazz Pharmaceuticals.
Michael Nolan Cook, PhD (Jazz Pharmaceuticals) Dr. Cook has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Cook has stock in Jazz Pharmaceuticals.
Julia Pitino (Aetion, Inc.) Miss Pitino has received personal compensation for serving as an employee of Aetion, Inc. Miss Pitino has stock in Aetion, Inc.
Helen Latimer, Other (Aetion, Inc.) Ms. Latimer has received personal compensation for serving as an employee of Aetion. Ms. Latimer has stock in Aetion.
Elizabeth C. Dabrowski, Jr., Other Ms. Dabrowski has received personal compensation for serving as an employee of Aetion, Inc.. Ms. Dabrowski has received stock or an ownership interest from AbbVie Inc.. Ms. Dabrowski has received stock or an ownership interest from BioMarin Pharmaceutical Inc.. Ms. Dabrowski has received stock or an ownership interest from CVS Health Corporation . Ms. Dabrowski has received stock or an ownership interest from Moderna Inc.. Ms. Dabrowski has received stock or an ownership interest from Walgreens Boots Alliance.
William B. White, MD (University of Connecticut School of Medicine) Dr. White has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for JAZZ Pharmaceuticals.